Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma

Prospective, open, interventional, randomized, non-commercial trial

Trial Details

NCT ID
NCT07787429
Phase
PHASE2
Sponsor
Anna Raciborska
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Mifamurtide
  • Sorafenib
Locations (sample)
  • Warsaw, Mazovian, Poland|52.22977,21.01178

Key Eligibility Criteria

  • Age ≥ 5 to ≤ 30 years at the time of qualification.
  • Histopathologically confirmed osteosarcoma based on previous diagnostic tests.
  • Provision of written, informed consent to participate in the study, including treatment with mifamurtide and sorafenib, in accordance with current …
  • Participants of the Part I classified as high-risk.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →